| 51 |
27058977 | High-throughput screening and radioligand binding studies reveal monoamine oxidase-B as the primary binding target for d-deprenyl. | 2016 May 1 |
3 |
| 52 |
27061066 | Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis. | 2016 Apr 2 |
1 |
| 53 |
27373997 | Identification of Indole-Based Chalcones: Discovery of a Potent, Selective, and Reversible Class of MAO-B Inhibitors. | 2016 Aug |
1 |
| 54 |
24964753 | DSP4, a selective neurotoxin for the locus coeruleus noradrenergic system. A review of its mode of action. | 2015 Jan |
1 |
| 55 |
25249059 | Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. | 2015 Feb |
5 |
| 56 |
25514361 | Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein. | 2015 Feb 18 |
1 |
| 57 |
25532905 | Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives. | 2015 Feb 1 |
1 |
| 58 |
25572450 | Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region. | 2015 Sep |
1 |
| 59 |
25592412 | An explorative study regarding the effect of l-deprenyl on cognitive and functional recovery in patients after stroke. | 2015 Feb 15 |
2 |
| 60 |
25677185 | Design and synthesis of a MAO-B-selectively activated prodrug based on MPTP: a mitochondria-targeting chemotherapeutic agent for treatment of human malignant gliomas. | 2015 Apr |
1 |
| 61 |
25863936 | Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel anti-apoptotic function for neuroprotection. | 2015 Oct |
1 |
| 62 |
26164425 | Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease. | 2015 Jun |
1 |
| 63 |
26189013 | Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies. | 2015 Oct |
1 |
| 64 |
26337020 | Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. | 2015 Oct 1 |
1 |
| 65 |
26352677 | Novel 2H-chromen-2-one derivatives of resveratrol: Design, synthesis, modeling and use as human monoamine oxidase inhibitors. | 2015 Oct 20 |
1 |
| 66 |
24769350 | Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents. | 2014 Jun 10 |
1 |
| 67 |
24937131 | The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs. | 2014 |
1 |
| 68 |
22968599 | Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. | 2013 Mar |
2 |
| 69 |
23281824 | Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors. | 2013 Feb 14 |
1 |
| 70 |
23328949 | Synthesis, molecular modeling, and in vitro screening of monoamine oxidase inhibitory activities of some novel hydrazone derivatives. | 2013 Jun |
1 |
| 71 |
23410524 | An update on amine oxidase inhibitors: multifaceted drugs. | 2013 Jul 1 |
1 |
| 72 |
23420173 | Interaction of selegiline-loaded PLGA-b-PEG nanoparticles with beta-amyloid fibrils. | 2013 Jun |
2 |
| 73 |
23474901 | Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study. | 2013 May |
2 |
| 74 |
23506388 | The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease. | 2013 May |
1 |
| 75 |
23611731 | The opposite effect of isotype-selective monoamine oxidase inhibitors on adipogenesis in human bone marrow mesenchymal stem cells. | 2013 Jun 1 |
1 |
| 76 |
23620664 | Clinical significance of metallothioneins in cell therapy and nanomedicine. | 2013 |
1 |
| 77 |
24005822 | Selegiline reverses aβ₂₅₋₃₅-induced cognitive deficit in male mice. | 2013 Nov |
1 |
| 78 |
24012376 | Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B). | 2013 Nov 1 |
2 |
| 79 |
24204150 | Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report. | 2013 |
2 |
| 80 |
22065207 | Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. | 2012 Apr |
2 |
| 81 |
22086140 | Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes. | 2012 May |
2 |
| 82 |
22592509 | Selegiline: a reappraisal of its role in Parkinson disease. | 2012 May-Jun |
1 |
| 83 |
22691758 | Therapies in Parkinson's disease. | 2012 Aug |
1 |
| 84 |
22954444 | Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro. | 2012 Nov 15 |
1 |
| 85 |
23231395 | Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. | 2012 |
2 |
| 86 |
21075154 | Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. | 2011 Jan |
5 |
| 87 |
21224199 | Selegiline and rasagiline: twins or distant cousins? | 2011 Jan |
3 |
| 88 |
21423589 | Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. | 2011 Jan 20 |
2 |
| 89 |
21626552 | Milestones in Parkinson's disease therapeutics. | 2011 May |
1 |
| 90 |
21858609 | Effects of selegiline, a monoamine oxidase B inhibitor, on differentiation of P19 embryonal carcinoma stem cells, into neuron-like cells. | 2011 Sep |
5 |
| 91 |
21923198 | Synthesis of three novel fluorine-18 labeled analogues of L-deprenyl for positron emission tomography (PET) studies of monoamine oxidase B (MAO-B). | 2011 Oct 27 |
4 |
| 92 |
21939547 | Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. | 2011 Sep 22 |
1 |
| 93 |
21971003 | The pharmacology of selegiline. | 2011 |
1 |
| 94 |
22110357 | MAO-inhibitors in Parkinson's Disease. | 2011 Mar |
1 |
| 95 |
22133327 | Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. | 2011 Dec 1 |
1 |
| 96 |
25205926 | Cell based therapies in Parkinson's Disease. | 2011 Apr |
1 |
| 97 |
19939587 | A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. | 2010 Mar 1 |
4 |
| 98 |
20022592 | A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. | 2010 May 1 |
2 |
| 99 |
20195940 | [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease]. | 2010 Mar |
1 |
| 100 |
20644207 | Changes in smoking expectancies in abstinent, reducing, and non-abstinent participants during a pharmacological trial for smoking cessation. | 2010 Sep |
1 |